Cover Image
市場調查報告書

代謝症候群的開發中產品分析

Metabolic Syndrome - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 192703
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
代謝症候群的開發中產品分析 Metabolic Syndrome - Pipeline Review, H1 2014
出版日期: 2014年03月31日 內容資訊: 英文 95 Pages
簡介

所謂代謝症候群是會提高心臟疾病及其他健康問題(醣尿病、腦中風等)危險性的一連串風險要素之名稱。主要症狀有肥胖病及高血壓、高血醣、高膽固醇症等。致病風險因子為年齡及人種、肥胖、糖尿病及其他疾病(非酒精性脂肪性肝疾病,多囊性卵巢症候群及其他)等。

本報告提供全球各國治療代謝症候群(內臟脂肪症候群)用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

代謝症候群概要

治療藥的開發

  • 代謝症候群開發中產品:概要
  • 代謝症候群開發中產品:比較分析

各企業開發中的代謝症候群治療藥

大學/研究機關研究中的代謝症候群治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

代謝症候群治療藥:開發中的產品一覽(各企業)

代謝症候群治療藥:研究中的產品一覽(大學/研究機關別)

代謝症候群治療藥的開發企業

  • 大日本住友製藥
  • Ildong Pharmaceutical Co., Ltd.
  • Chipscreen Biosciences Ltd
  • Abeille Pharmaceuticals, Inc.
  • Cortendo Invest AB
  • Spherix Incorporated
  • Ache Laboratorios Farmaceuticos S/A
  • Indus Biotech Private Limited
  • Cardax Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Poxel SA
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Lead Discovery Center GmbH
  • MI.TO. Technology S.r.L.

代謝症候群:治療藥的評估

  • 單劑治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • CS-038
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ACH-09
  • MBX-8025
  • Chloroquine
  • epurerenon
  • SPX-10624258
  • MB-12066
  • AB-3001
  • CDX-085
  • CDE-001
  • GQ-16
  • 下一代型皮質醇抑制劑
  • ND-630
  • AMPD2標的醫藥品
  • KH-064
  • 代謝症候群計劃
  • 代謝症候群計劃
  • 惡病質·代謝症候群·心臟衰竭β3腎上腺素受體的緩和用小分子
  • 發炎性疾病小分子
  • Myonectin
  • ID-2244
  • ZLN-024
  • C-24
  • Drug Targeting Farnesoid X Receptor
  • Apoptosis Inhibitor Of Macrophages
  • Small Molecule for Cardiovascular And Metabolic Disorders
  • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders
  • Drugs Targeting Acetyl-CoA Carboxylase
  • 11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors
  • Drug Targeting SIRT
  • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders
  • TGR-5 Agonist Program
  • INDUS-810

代謝症候群治療藥:開發中產品的最新趨勢

代謝症候群治療藥:暫停開發的產品

代謝症候群治療藥:中止開發的產品

代謝症候群相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全6件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4691IDB

Global Markets Direct's, 'Metabolic Syndrome - Pipeline Review, H1 2014', provides an overview of the Metabolic Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metabolic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metabolic Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metabolic Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metabolic Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metabolic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metabolic Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metabolic Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Metabolic Syndrome - Overview
    • Pipeline Products for Metabolic Syndrome - Comparative Analysis
  • Metabolic Syndrome - Therapeutics under Development by Companies
  • Metabolic Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Metabolic Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Metabolic Syndrome - Products under Development by Companies
  • Metabolic Syndrome - Products under Investigation by Universities/Institutes
  • Metabolic Syndrome - Companies Involved in Therapeutics Development
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Ildong Pharmaceutical Co., Ltd.
    • Chipscreen Biosciences Ltd
    • Abeille Pharmaceuticals, Inc.
    • Cortendo Invest AB
    • Spherix Incorporated
    • Ache Laboratorios Farmaceuticos S/A
    • Indus Biotech Private Limited
    • Cardax Pharmaceuticals, Inc.
    • VivaCell Biotechnology Espana S.L.
    • Poxel SA
    • Shanghai Pharmaceuticals Holding Co Ltd
    • Lead Discovery Center GmbH
    • MI.TO. Technology S.r.L.
  • Metabolic Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CS-038 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACH-09 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chloroquine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eplerenone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPX-10624258 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MB-12066 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AB-3001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDX-085 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CDE-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GQ-16 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Next Generation Cortisol Inhibitor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ND-630 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting AMPD2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KH-064 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Metabolic Syndrome Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Metabolic Syndrome Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myonectin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ID-2244 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZLN-024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-24 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting Farnesoid X Receptor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Apoptosis Inhibitor Of Macrophages - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cardiovascular And Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs Targeting Acetyl-CoA Carboxylase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting SIRT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TGR-5 Agonist Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INDUS-810 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metabolic Syndrome - Recent Pipeline Updates
  • Metabolic Syndrome - Dormant Projects
  • Metabolic Syndrome - Discontinued Products
  • Metabolic Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Nov 11, 2013: Micardis crosses 50 million patient-years of experience on 15th anniversary
      • Aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound CDX-085
      • Apr 26, 2012: miRagen Announces Publication Of Data On MIRG-9103 In Journal Cell
      • Feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of KD025
      • Sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome
      • Jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metabolic Syndrome, H1 2014
  • Number of Products under Development for Metabolic Syndrome - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Metabolic Syndrome - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
  • Metabolic Syndrome - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2014
  • Metabolic Syndrome - Pipeline by Chipscreen Biosciences Ltd, H1 2014
  • Metabolic Syndrome - Pipeline by Abeille Pharmaceuticals, Inc., H1 2014
  • Metabolic Syndrome - Pipeline by Cortendo Invest AB, H1 2014
  • Metabolic Syndrome - Pipeline by Spherix Incorporated, H1 2014
  • Metabolic Syndrome - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014
  • Metabolic Syndrome - Pipeline by Indus Biotech Private Limited, H1 2014
  • Metabolic Syndrome - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014
  • Metabolic Syndrome - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014
  • Metabolic Syndrome - Pipeline by Poxel SA, H1 2014
  • Metabolic Syndrome - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014
  • Metabolic Syndrome - Pipeline by Lead Discovery Center GmbH, H1 2014
  • Metabolic Syndrome - Pipeline by MI.TO. Technology S.r.L., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Metabolic Syndrome Therapeutics - Recent Pipeline Updates, H1 2014
  • Metabolic Syndrome - Dormant Projects, H1 2014
  • Metabolic Syndrome - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Metabolic Syndrome, H1 2014
  • Number of Products under Development for Metabolic Syndrome - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top